Merck News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

20.12.06	FDA Approves New Indication for INVANZ(R) (ertapenem) for the Prevention of Surgical Site Infections (SSI) following Elective Colorectal Surgery in Adults (Businesswire)
13.12.06	Merck Wins Federal VIOXX(R) Product Liability Case (Businesswire)
05.12.06	New Data Show Significant Reductions in Both Post-Meal and Fasting Blood Sugar Levels with Sitagliptin Phosphate Plus Metformin as Initial Therapy in Patients with Type 2 Diabetes (Businesswire)
04.12.06	Merck and Neuroptix Collaborate on Early Alzheimer's Diagnostics Using Laser Eye Scanning (Businesswire)
01.12.06	Merck Announces JANUMET(TM), the Trademark for its Investigational Combination Therapy of Sitagliptin Phosphate and Metformin for Type 2 Diabetes (Businesswire)
22.11.06	Statement Regarding Dismissal of Personal Injury Class-Action Lawsuit (Businesswire)
17.11.06	MSD's Prüfsubstanz MK-0524 reduzierte durch Extended-Release Niacin mit Langzeitwirkung hervorgerufene Flushing-Reaktionen in einer Phase II-Studie (Businesswire)
13.11.06	Merck Launches National Advertising Campaign for GARDASIL(R), Merck's New Cervical Cancer Vaccine (Businesswire)
03.11.06	Merck & Co., Inc. Introduces New 14th Edition of The Merck Index, with Companion CD-ROM (Businesswire)
18.10.06	JANUVIA(TM) einmal täglich, der erste und in den USA einzige für Typ-2-Diabetes verfügbare DPP-4-Hemmer (Dipeptidyl-Peptidase-Inhibitor) von der FDA zugelassen. (Businesswire)
09.10.06	FDA Approves ZOLINZA(TM) (Vorinostat) for the Treatment of Cutaneous Manifestations in Patients with Cutaneous T-Cell Lymphoma Who Have Tried and Failed Other Therapies (Businesswire)
07.10.06	FDA Approves ZOLINZA(TM) (Vorinostat) for the Treatment of Cutaneous Manifestations in Patients with Cutaneous T-Cell Lymphoma Who Have Tried and Failed Other Therapies (Businesswire)
26.09.06	Merck Wins Federal VIOXX(R) Product Liability Case: Smith v. Merck & Co., Inc. (Businesswire)
02.08.06	Merck & Co., Inc. Conference Call and Audio Web Cast (Businesswire)
24.07.06	Merck Announces Strong Financial Results for the Second Quarter 2006 (Businesswire)
17.07.06	Rosetta Biosoftware Licenses the Rosetta Resolver Expression Data Analysis System to University of Nebraska-Lincoln (Businesswire)
13.07.06	Merck Wins New Jersey VIOXX(R) Product Liability Case; Jury Rejects Claims of Long-Term VIOXX User (Businesswire)
29.06.06	CDC Advisory Committee on Immunization Practices Unanimously Recommends Addition of a Second Dose of Chickenpox-Containing Vaccine to Childhood Immunization Schedule (Businesswire)
26.06.06	Merck Stands Behind Original APPROVe Study Results; Increased Relative Risk Observed Beginning After 18 Months (Businesswire)
21.06.06	Phase II Studies Show Investigational Insomnia Agent Gaboxadol Improved Deep Sleep and Key Sleep Measures in Adults with Primary and Transient Insomnia (Businesswire)
19.06.06	REPEAT/New Study Showed VYTORIN(R) (ezetimibe/simvastatin) Significantly More Effective than Crestor(R) (rosuvastatin) at Lowering LDL ''Bad'' Cholesterol At All Doses Compared (Businesswire)
18.06.06	New Study Showed VYTORIN(R) (ezetimibe/simvastatin) Significantly More Effective than Crestor(R) (rosuvastatin) at Lowering LDL ''Bad'' Cholesterol At All Doses Compared (Businesswire)
12.06.06	REPEAT/New Study Showed VYTORIN(R) (ezetimibe/simvastatin) Superior to Lipitor in Reducing LDL ''Bad'' Cholesterol in Patients with Type II Diabetes at the Recommended Usual Starting Doses (Businesswire)
10.06.06	New Study Showed VYTORIN(R) (ezetimibe/simvastatin) Superior to Lipitor in Reducing LDL ''Bad'' Cholesterol in Patients with Type II Diabetes at the Recommended Usual Starting Doses (Businesswire)
09.06.06	FDA Approves New Indication for ZETIA(R) (ezetimibe) - Merck/Schering-Plough's Cholesterol Lowering Drug - For Administration in Combination with Fenofibrate, along With Diet (Businesswire)
07.06.06	ZOLINZA(TM), Merck's Investigational Medicine for Advanced Cutaneous T-Cell Lymphoma (CTCL), to Receive Priority Review from U.S. Food and Drug Administration (Businesswire)
11.05.06	Merck Announces Preliminary Analyses of Off-Drug Extension of APPROVe Study (Businesswire)
09.05.06	Merck & Co., Inc. to Acquire Abmaxis, Inc.; Acquisition Further Enhances Merck Commitment and Capabilities in Biologics Research and Development (Businesswire)
09.05.06	Merck & Co., Inc. to Acquire GlycoFi, Inc.; Acquisition Enhances Merck Capabilities in Biologics Research and Development (Businesswire)
25.04.06	Merck Well-Positioned to Regain Industry-Leadership Position, CEO Tells Stockholders (Businesswire)
11.04.06	Merck to Appeal Punitive and Compensatory Verdicts In New Jersey VIOXX(R) Product Liability Case; Merck Pleased that New Jersey Jury Rejected Failure to Warn Claim By One of Two Long-Term VIOXX Users (Businesswire)
20.03.06	Neuromed Pharmaceuticals and Merck & Co., Inc. Announce Agreement for Novel N-type Calcium Channel Compounds (Businesswire)
13.03.06	New Analysis Showed VYTORIN(R) (ezetimibe/simvastatin) Superior to Lipitor(R) in Achieving Lower Levels of LDL (''bad'') Cholesterol, Apolipoprotein B and C-Reactive Protein (Businesswire)
09.03.06	Merck and Paratek Pharmaceuticals Sign Collaboration Agreement for Novel Antibiotic PTK 0796 Currently in Phase 1 Testing (Businesswire)
02.03.06	The Merck Patient Assistance Program Remains an Option for Many Medicare Beneficiaries (Businesswire)
27.02.06	Rosetta Biosoftware führt Version 6.0 des Systems zur Genexpressionsdatenanalyse Rosetta Resolver ein (Businesswire)
03.02.06	FDA Approves Merck's ROTATEQ(R), The Only Vaccine in the U.S. to Prevent Rotavirus Gastroenteritis, a Leading Cause of Severe Infant Diarrhea; ROTATEQ Fits Into Routine Well-Baby Visit Schedule (Businesswire)
11.01.06	FDA Approves EMEND(R) (aprepitant), in Combination with Other Antiemetics, for the Prevention of Nausea and Vomiting in Cancer Patients Undergoing Moderately Emetogenic Chemotherapy (Businesswire)
10.01.06	VIOXX(R) Trial Update: Statement on VIOXX(R) Product Liability Trial Scheduled in Starr County, Texas (Businesswire)
12.12.05	Hung Jury in First Federal VIOXX(R) Product Liability Trial (Businesswire)
28.11.05	Merck Announces Initial Steps In Global Restructuring Program (Businesswire)
18.11.05	Results of an Initial Phase II Study Showed That MK-0518, an Investigational Integrase Inhibitor, Provided Superior Reduction in HIV Viral RNA vs. Placebo in Treatment-Naive HIV-infected Patients (Businesswire)
15.11.05	Merck/Schering-Plough Announces Update for the IMPROVE-IT Trial (Businesswire)
14.11.05	FDA Approves New Indication for INVANZ(R) (ertapenem) for the Treatment of Moderate to Severe Complicated Foot Infection in Diabetic Patients without Osteomyelitis (Businesswire)
31.10.05	Merck und Bristol-Myers Squibb lizenzieren neue AIDS-Medikamente an IPM zur Entwicklung von Mikrobiziden zum Schutz von Frauen vor HIV (PR Newswire)
24.10.05	Merck Announces Third-Quarter 2005 Earnings Per Share (EPS) of 65 Cents (Businesswire)
03.10.05	Rosetta Biosoftware and Agendia to Deliver Diagnostic Utilities; Agendia Licenses the Rosetta Resolver System (Businesswire)
27.09.05	Merck Expands Katrina Prescription Replacement Program to Include Patients Impacted by Hurricane Rita (Businesswire)
09.09.05	Bristol-Myers Squibb and Merck Joint Statement on FDA Advisory Committee Vote on PARGLUVA(TM) (Muraglitazar), an Investigational Oral Treatment for Type 2 Diabetes (PR Newswire)
18.08.05	Indications for Merck's SINGULAIR(R) Expand with FDA Approval for Perennial Allergic Rhinitis; SINGULAIR Now Shown to Provide Relief from a Broad Range of Indoor and Outdoor Allergy Symptoms (Businesswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Givaudan	3’870.00	1.49 %	K V
Lonza Grp	513.60	1.14 %	K V
Swiss Re	125.25	0.20 %	K V
Holcim	88.46	0.11 %	K V
Kuehne+Nagel Int	210.40	0.00 %	K V
Logitech Intl	68.92	-1.20 %	K V
Part Grp Hldg	1’209.00	-1.47 %	K V
CieFinRichemont	118.90	-1.94 %	K V
Nestle	76.66	-1.94 %	K V
Sonova Hldg	300.40	-5.21 %	K V

mehr

19.11.24		Schwacher Handel: Dow Jones beendet den Dienstagshandel mit Verlusten
19.11.24		Gute Stimmung in New York: NASDAQ 100 letztendlich im Plus
19.11.24		Schwacher Handel: Dow Jones legt am Dienstagnachmittag den Rückwärtsgang ein
19.11.24		Gewinne in New York: NASDAQ 100 legt zu
19.11.24		Dow Jones-Handel aktuell: So entwickelt sich der Dow Jones aktuell
19.11.24		Schwache Performance in Europa: Euro STOXX 50 zeigt sich zum Handelsende schwächer
19.11.24		Angespannte Stimmung in Europa: STOXX 50 verliert schlussendlich